Mirum Pharmaceuticals, Inc. filings document operating results, product-sales disclosures, clinical program updates and governance matters for a rare disease biopharmaceutical company. Its 8-K reports furnish earnings releases, preliminary sales information, Regulation FD investor materials and other event disclosures tied to LIVMARLI, CHOLBAM, CTEXLI and investigational programs such as volixibat and brelovitug.
The company’s SEC record also covers capital-structure and transaction disclosures, including the completed Bluejay Therapeutics acquisition, related pro forma financial information and a PIPE financing. Proxy filings describe annual meeting matters, board elections, executive compensation and equity-plan governance, while registration details identify Mirum common stock as listed on the Nasdaq Global Market under MIRM.
GREY MICHAEL G reported acquisition or exercise transactions in this Form 4 filing.
Mirum Pharmaceuticals director Michael G. Grey received new equity compensation awards. On June 15, 2026, he was granted 1,980 restricted stock units, each representing a right to receive one share of common stock, and 3,772 stock options exercisable at $101.00 per share.
Both the RSUs and options are scheduled to vest on the first anniversary of the grant date, but will in any case be fully vested on the date of Mirum’s 2027 annual stockholder meeting. After these grants, Grey directly holds 1,980 RSUs and 3,772 options, with the options expiring on June 14, 2036.
MIRM proposed sale notice filed on 06/17/2026 lists 2,594 shares of Common stock offered for sale through Morgan Stanley Smith Barney LLC. The filing breaks the shares into 1,205 Performance Shares (03/15/2026), 722 Restricted Stock (01/06/2024) and 667 Restricted Stock (07/01/2024).
Mirum Pharmaceuticals, Inc. Chief Financial Officer Eric Bjerkholt exercised stock options and sold shares in the company. On June 9, 2026, he exercised 2,393 Employee Stock Options at an exercise price of $26.49 per share, receiving the same number of common shares. On June 8, 2026, he sold a total of 5,000 common shares in open-market transactions at weighted average prices of $92.84, $93.95 and $95.12, within the disclosed trading ranges. The filing states these transactions were made pursuant to a pre-arranged Rule 10b5-1 Plan. Following these transactions, Bjerkholt directly owns 47,181 common shares of Mirum Pharmaceuticals.
Mirum Pharmaceuticals President and COO Peter Radovich exercised stock options to acquire 16,988 shares of common stock at $19.19 per share. These options were fully vested at the time of exercise. After the transaction, he directly holds 57,260 shares of Mirum common stock.
Following the exercise, Radovich still holds 48,012 stock options with an exercise price of $19.19 per share, expiring on January 6, 2031. The filing reflects a derivative exercise only, with no open-market share sales reported in this transaction.
MIRM affiliate filed a Form 144 proposing the sale of 5,000 shares of Common Stock. The filing lists the securities as Restricted Stock with an effective date of 09/11/2024.
The filing also reports a prior sale by Eric Bjerkholt of 7,287 shares on 03/16/2026 for $670,242.96.
Mirum Pharmaceuticals, Inc. director and chief executive officer Christopher Peetz reported option exercises and share sales in the company’s stock. On June 1, 2026, he exercised stock options for 30,000 shares of common stock at an exercise price of $2.936 per share and sold 30,000 shares of common stock in multiple open-market transactions. The sales occurred at prices ranging from about $93.90 to $99.79 per share pursuant to a pre-arranged Rule 10b5-1 Plan adopted on March 2, 2026. Following these transactions, he holds 194,309 shares of common stock directly and 187,500 shares indirectly through The Peetz Family Trust, as well as 128,487 stock options outstanding.
Director Timothy P. Walbert of Mirum Pharmaceuticals, Inc. exercised previously granted restricted stock units that converted into 3,977 shares of common stock on May 29, 2026. These units represented a contingent right to receive one share of common stock for each unit.
After the transaction, Walbert directly holds 9,680 shares of common stock. The filing shows a routine compensation-related derivative exercise, with no open-market buying or selling and no remaining restricted stock units from this grant.
Mirum Pharmaceuticals director Lon Cardon exercised 3,977 restricted stock units into common stock. These units each converted into one share on May 29, 2026, increasing his directly held common stock to 9,680 shares. The filing shows an equity award vesting, with no open‑market buying or selling.
Mirum Pharmaceuticals director Saira Ramasastry reported an exercise-and-sale transaction involving 3,977 shares of common stock. On May 29, 2026, 3,977 restricted stock units were converted into 3,977 shares of common stock at a stated price of $0.0000 per share. On June 1, 2026, all 3,977 shares were sold in an open-market transaction at $100.0000 per share, leaving 0 shares of common stock reported as directly held after the sale. The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 18, 2025, indicating the timing was set in advance.
Mirum Pharmaceuticals director Laurent Fischer exercised restricted stock units into common shares. On May 29, 2026, 3,977 restricted stock units, each representing a right to receive one share of common stock, were converted into 3,977 shares of Mirum common stock. Following this derivative exercise, Fischer directly holds 10,727 shares of common stock. The restricted stock units represented a contingent right that vested on May 29, 2026.